共 171 条
[11]
Ajiki W(2016)Extending aromatase-inhibitor adjuvant therapy to 10 years N Engl J Med 375 209-219
[12]
Sobue T(2007)Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845-1853
[13]
Kurebayashi J(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol 37 423-438
[14]
Miyoshi Y(2019)Progress in adjuvant systemic therapy for breast cancer Nat Rev Clin Oncol. 16 27-44
[15]
Ishikawa T(2018)Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5 J Clin Oncol 36 1941-1948
[16]
Saji S(1998)Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155-168
[17]
Sugie T(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013
[18]
Suzuki T(2020)Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value Sci Rep. 10 4660-643
[19]
Uchida K(2009)Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631-144
[20]
Ohashi H(2006)Activation of PI3K/Akt signaling and hormone resistance in breast cancer Breast Cancer. 13 137-2795